Magenta Therapeutics is focused on developing a range of innovative medicines that leverage stem cell transplants to cure patients with autoimmune diseases, genetic diseases, and blood cancers, among others. Their clinical-stage portfolio includes highly promising drugs such as MGTA-117, which is designed to target mutated stem cells known to cause acute myeloid leukemia and myelodysplastic syndromes, among other afflictions. The company also has a cell therapy program, E478, which has emerged as a leading small molecule aryl hydrocarbon receptor antagonist for stem cell-based gene therapy and genome editing.